Bionomics (OTCMKTS:BNOEF) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday.
Separately, Zacks Investment Research lowered Bionomics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 18th.
Shares of OTCMKTS:BNOEF opened at $0.10 on Thursday. Bionomics has a one year low of $0.10 and a one year high of $0.70.
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments.
Recommended Story: Outstanding Shares and The Effect on Share Price
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.